1-7 of 7
Zhumei Zhan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy and safety of Golidocitinib-based first line regimen in peripheral T-cell lymphoma: A multicenter retrospective study

Free
Zhumei Zhan, Peipei Li, Xianghua Wang, Changqing Zhen, Junqing Xu, Jie Yu, Ji Ma, Beibei Lv, Xin Liu, Ken H. Young, Xiaosheng Fang
Journal: Blood
Blood (2025) 146 (Supplement 1): 7157.
https://doi.org/10.1182/blood-2025-7157
Published: 2025
Journal Articles

Efficacy and safety of RCD pulse regimen for acquired Hemophilia A

Free
Xianghua Wang, Peipei Li, Ya Zhang, Zhumei Zhan, Cheng Zhang, Changqing Zhen, Juan Fan, Xiaosheng Fang, Xiangxiang Zhou
Journal: Blood
Blood (2025) 146 (Supplement 1): 1314.
https://doi.org/10.1182/blood-2025-1314
Published: 2025
Journal Articles

Comparative efficacy and safety of obinutuzumab- versus rituximab-based immunochemotherapy in newly diagnosed burkitt lymphoma: A single-center retrospective study

Free
Ying Zhang, Wei Guo, Haotian Wang, Luming Cao, Jihong Xu, Xin Wan, Jia Li, Zhumei Zhan, Rui Xing, Ou Bai
Journal: Blood
Blood (2025) 146 (Supplement 1): 6886.
https://doi.org/10.1182/blood-2025-6886
Published: 2025
Journal Articles

Chidamide: A New Exploration of Maintenance Therapy for DLBCL Patients with HBV Infection

Free
Ying Zhang, Wei Guo, Yangzhi Zhao, Zhumei Zhan, Haotian Wang, Zhe Li, Bowen Wang, Luming Cao, Xin Wan, Jia Li, Ou Bai
Journal: Blood
Blood (2024) 144 (Supplement 1): 4490.
https://doi.org/10.1182/blood-2024-204677
Published: 2024
Journal Articles

The Short-Term Efficacy and Safety of Obinutuzumab Plus Chemotherapy in B-NHL with High Tumor Burden: A Real-World, Retrospective Study

Free
Xin Wan, Wei Guo, Xingtong Wang, Yangzhi Zhao, Jia Li, Junna Li, Zhumei Zhan, Ou Bai
Journal: Blood
Blood (2022) 140 (Supplement 1): 11977–11978.
https://doi.org/10.1182/blood-2022-169343
Published: 2022
Journal Articles

Clinical Features and Prognosis of Double Primary Malignant Neoplasms in Patients with Non-Hodgkin Lymphoma

Free
Zhumei Zhan, Wei Guo, Xingtong Wang, Jia Li, Xin Wan, Ou Bai
Journal: Blood
Blood (2022) 140 (Supplement 1): 11968–11969.
https://doi.org/10.1182/blood-2022-169463
Published: 2022
Journal Articles

Bortezomib: Once-Weekly 1.6mg/m 2 Maybe a Better Choice Compared with Twice-Weekly 1.3mg/m 2 in Newly Dignosed Multiple Myeloma

Free
Yubin Li, Fangfang Li, Wangshan Song, Zhumei Zhan, Xiangxin Li, Lingling Wang, Fanglin Li, MD, Ming Hou, MD PhD, Hao Li, MD, Luqun Wang, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5558.
https://doi.org/10.1182/blood-2019-125714
Published: 2019